Bringing the Oncology Community Together

Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows

Beth Fand Incollingo
Published Online: Saturday, June 2, 2012
Dr. Bernard J. Escudier

Bernard J. Escudier, MD

More than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib, according to the results of a randomized, controlled, double-blind study released June 1 during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). The finding will be helpful in maintaining quality of life for this population of patients, some of whom may remain on cancer therapies for years, said Bernard J. Escudier, MD, a physician at the Institut Gustave Roussy, Villejuif, France, and the study’s lead author.

Escudier said the investigation was an opportunity to learn more about side effects in a field that has enjoyed a recent explosion of new drugs, but that doesn’t offer clear evidence about which first-line treatment is the safest and most effective for metastatic patients. Pazopanib (Votrient, GlaxoSmithKline [GSK]) and sunitinib (Sutent, Pfizer) are kinase inhibitors.

“While we expected patients would prefer one drug over the other due to the known toxicity profiles, we didn’t expect this great a preference,” Escudier said of the results of the PISCES study, funded by GSK. “It’s an important reminder that the low-grade toxicities patients experience may not seem bad, but if you are experiencing the toxicity over a long time, it has an effect on your quality of life.”

In the year-long study that began in 2010, 168 patients were randomized to pazopanib for 10 weeks, took a two-week break from medication, and then received sunitinib for 10 weeks, or vice versa. In the primary analysis of 114 patients, pazopanib was preferred by 70% and sunitinib by 22%. Eight percent had no preference.

Patients most commonly cited better quality of life and less fatigue as their reasons for preferring pazopanib. In addition, patients on pazopanib noticed fewer changes in the way food tasted, Escudier said. While there were slightly more incidences of diarrhea and liver enzyme elevation with pazopanib, reports of hand and foot soreness, asthenia, and mucositis-dermatitis were less frequent, added study co-author Faisal Mehmud, MD, clinical development director, GSK Global Oncology.

Patients had fewer dose reductions on pazopanib than on sunitinib (13% vs 20%), and fewer interruptions in treatment (6% vs 12%).

Physicians were asked to participate in the study because of their awareness not just of symptomatic toxicities of the two drugs, but of asymptomatic toxicities, such as hypertension, Mehmud said. Of the physicians who participated, 60% preferred pazopanib, 21% preferred sunitinib, and 19% had no preference.

OncLive TV Exclusive

The PISCES study was innovative because it considered “how patients feel when they take a drug over many months,” a factor that traditional adverse event reporting does not reflect, Escudier said. He suggested that the study’s design can serve as a model for other investigators. According to Mehmud, the investigation relied on the administration of questionnaires including the validated Functional Assessment of Chronic Illness Therapy measurement of fatigue and a three-question quality-of-life query created for the PISCES study by GSK and the researcher who developed FACIT, David Cella, PhD, professor and chair of the Department of Medical Social Sciences at the Northwestern University Feinberg School of Medicine, in Chicago.

A related study, the COMPARZ trial, is comparing the efficacy of pazopanib and sunitinib in about 1,000 patients. The trial’s endpoint is progression-free survival, Escudier said, and results are expected soon.


Escudier BJ, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)—PISCES study, NCT 01064310. J Clin Oncol. 2012;30(suppl; abstr CRA4502).

<<< View more from the 2012 ASCO Conference

Related Articles
Cytoreductive Nephrectomy in Untreated Metastatic RCC
In this segment, panelists explore whether cytoreductive nephrectomy should be performed before or after the administration of targeted therapies for patients with untreated metastatic renal cell carcinoma.
Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death
A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.